Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. The company also markets DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. Its development pipeline comprises DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain; and DepoTranexamic Acid, a pre-clinical development product for the treatment or prevention of excessive blood loss during surgery by promoting hemostasis. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010.

Parsippany-Troy Hills, US
487 (est)

Pacira Pharmaceuticals Locations

Parsippany-Troy Hills, US
San Diego, US
San Diego, US
New York, US

Pacira Pharmaceuticals Metrics

Pacira Pharmaceuticals Summary

Founding Date


Market capitalization

$1.36 B

Closing share price


Pacira Pharmaceuticals Market Value History

Pacira Pharmaceuticals News

Pacira Pharmaceuticals Company Life